|
Our immune systems can efficiently identify and
destroy abnormal cells. For many years, scientists have debated whether this
immune surveillance can efficiently pickup cancer
cells and destroy them spontaneously. It is encouraging that white blood
cells from a naturally mutated mouse are found to kill aggressive cancer
cells. Normal mice injected with the white blood cells from the mutated
mice acquired systemic resistance to protect them from developing cancers.
Whether this phenomenon in mice can be found in humans needs further
investigation. Markedly, we found in our laboratory that a partially purified
protein fraction could activate human blood to specifically kill breast
cancer cells in vitro. Our study demonstrated that this cancer-specific
killing acts through the Complement system, an ancient immune
surveillance system to destroy infected and other abnormal cells. We thus hypothesize that human complement
is also capable of acquiring the specificity to kill breast cancer cells;
however, it lacks a factor that specifically initiates the killing process.
In this proposal, we plan to identify 1) the activation factor and 2) the
targeted molecules on the surface of human breast cancer cells. Methodologies
will involve development of novel affinity chromatographs and application of
mass spectrometry-based proteomic approaches. These aims are straightforward
and feasible based on our preliminary studies. Accomplishing these
experiments will allow us to confirm their function of the activation factor
and characterize the mechanism of how these proteins specifically activate
our innate immunity to fight breast cancer. Results of the proposed study
will become the basis that may lead to development of new strategies for drug
discovery. It may explain, at least in part, why some people never get
cancer.

|